Examining the efficacy, safety, and patient acceptability of the etonogestrel implantable contraceptive

Patient Preference and Adherence

Volumn 3, Issue , 2009, Pages 205-211

  Hohmann, Heather ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Contraception; ENG implant; Implanon ; Progestin only

Indexed keywords

EID: 79952572526     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S4299     Document Type: Review

References (35)

1. Flores JB, Balderas ML, Bonilla MC, Vazquez-Estrada L. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. Int J Gynaecol Obstet. 2005;90(3):228-233.
2. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999;14(4):976-981.
3. Implanon (package insert). Roseland, NJ: Organon USA Inc; 2006.
4. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception. 2002;65(1):21-27.
5. Wenzl R, van Beek A, Schnabel P, Huber J. Pharmacokinetics of etonogestrel released from the contraceptive implant Implanon. Contraception. 1998;58(5):283-288.
6. Makarainen L, van Beek A, Tuomivaara L, Asplund B, Coelingh Bennink H. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. Fertil Steril. 1998; 69(4):714-721.
7. Davies GC, Feng LX, Newton JR, Van Beek A, Coelingh-Bennink HJ. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception. 1993;47(3):251-261.
8. Diaz S, Pavez M, Moo-Young AJ, Bardin CW, Croxatto HB. Clinical trial with 3-keto-desogestrel subdermal implants. Contraception. 1991;44(4):393-408.
9. Croxatto HB, Makarainen L. The pharmacodynamics and efficacy of Implanon. An overview of the data. Contraception. 1998; 58(6 Suppl):91S-97S.
10. IMPLANON approval letter: US Food and Drug Administration; 2006.
11. Inal MM, Yildirim Y, Ertopcu K, Avci ME, Ozelmas I, Tinar S. Effect of the subdermal contraceptive etonogestrel implant (Implanon) on biochemical and hormonal parameters (three years follow-up). Eur J Contracept Reprod Health Care. 2008;13(3):238-242.
12. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril. 17 2008.
13. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception. 1999;60(1):1-8.
14. Harrison-Woolrych M, Hill R. Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia. Contraception. 2005;71(4):306-308.
15. Shulman LP, Gabriel H. Management and localization strategies for the nonpalpable Implanon rod. Contraception. 2006;73(4): 325-330.
16. Funk S, Miller MM, Mishell DR Jr, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005;71(5):319-326.
17. Lantz A, Nosher JL, Pasquale S, Siegel RL. Ultrasound characteristics of subdermally implanted Implanon contraceptive rods. Contraception. 1997;56(5):323-327.
18. Westerway SC, Picker R, Christie J. Implanon implant detection with ultrasound and magnetic resonance imaging. Aust N Z J Obstet Gynaecol. 2003;43(5):346-350.
19. Pymar HC, Creinin MD, Schwartz JL. "Pop-out" method of levonorgestrel implant removal. Contraception. 1999;59(6):383-387.
20. Bitzer J, Tschudin S, Alder J. Acceptability and side-effects of Implanon in Switzerland: a retrospective study by the Implanon Swiss Study Group. Eur J Contracept Reprod Health Care. 2004;9(4): 278-284.
21. Witjaksono J, Lau TM, Affandi B, Rogers PA. Oestrogen treatment for increased bleeding in Norplant users: preliminary results. Hum Reprod. 1996;(11 Suppl 2):109-114.
22. Weisberg E, Hickey M, Palmer D, et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum Reprod. 2006;21(1):295-302.
23. Alvarez-Sanchez F, Brache V, Thevenin F, Cochon L, Faundes A. Hormonal treatment for bleeding irregularities in Norplant implant users. Am J Obstet Gynecol. 1996;174(3):919-922.
24. Croxatto HB. Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care. 2000; (5 Suppl 2):21-28.
25. Walch K, Unfried G, Huber J, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception. 2009;79(1):29-34.
26. Edwards JE, Moore A. Implanon. A review of clinical studies. Br J Fam Plann. 1999;24(4 Suppl):3-16.
27. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception. 2006;74(4):287-289.
28. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device. Contraception. 2000;62(5):239-246.
29. Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant Implanon and a nonmedicated intrauterine device on the growth of breast-fed infants. Contraception. 2006;73(4):368-371.
30. Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod. 2000;15(1):118-122.
31. Monteiro-Dantas C, Espejo-Arce X, Lui-Filho JF, Fernandes AM, Monteiro I, Bahamondes L. A three-year longitudinal evaluation of the forearm bone density of users of etonogestrel-and levonorgestrelreleasing contraceptive implants. Reprod Health. 2007;4:11.
32. Biswas A, Viegas OA, Roy AC. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids-a randomized comparative study. Contraception. 2003;68(3):189-193.
33. Merki-Feld GS, Imthurn B, Seifert B. Effects of the progestagen-only contraceptive implant Implanon on cardiovascular risk factors. Clin Endocrinol (Oxf). 2008;68(3):355-360.
34. Biswas A, Biswas S, Viegas OA. Effect of etonogestrel subdermal contraceptive implant (Implanon) on liver function tests-a randomized comparative study with Norplant implants. Contraception. 2004; 70(5):379-382.
35. Hatcher R, Trussell J, Stewart F, et al. Kowal D. Contraceptive Technology. 19th Revised ed. New York: Ardent Media, Inc; 2007.